Anita Mamtani1, Sujata Patil2, Michelle Stempel1, Monica Morrow3. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrowm@mskcc.org.
Abstract
BACKGROUND: Randomized trials demonstrate equivalent locoregional control with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) for T1-2 micrometastatic breast cancer, but include few mastectomy patients. Consensus is lacking on indications for post-mastectomy radiotherapy (PMRT) in this population. Herein, we evaluate locoregional recurrence (LRR) in an unselected, modern cohort of T1-2 breast cancer patients with micrometastases or isolated tumor cells (ITCs; N0i+/N1mi) having a mastectomy. METHODS: We identified patients with T1-2N0i+/N1mi breast cancer treated with mastectomy from January 2006 to December 2011. Recurrent, bilateral, and neoadjuvant cases were excluded. The primary outcome of interest was LRR. RESULTS: Overall, 352 patients [211 (60%) with ITCs and 141 (40%) with micrometastases] were identified. 162 (46%) patients had SLNB alone and one node was positive in 295 (84%) cases; 31 (9%) patients had PMRT and 95% had systemic therapy. At a median 6 years of follow-up, the overall crude LRR rate was 2.8% (n = 9), with no axillary recurrences, and the crude LRR rate was 3.9% among those who had SNB alone. Those with LRR had a median age of 55 years, median tumor size of 1.7 cm, and ductal histology; the majority were high-grade (89%) and estrogen receptor positive (78%), with one positive node (89%). There was no association between LRR and receipt of PMRT (p = 0.4), SLNB versus ALND (p = 0.2), or number of positive nodes (p = 0.7) using the log-rank test. CONCLUSIONS: LRR was infrequent among T1-2N0i+/N1mi patients treated with mastectomy without PMRT, with no axillary failures, suggesting that PMRT or nodal radiotherapy are not routinely indicated in this population.
BACKGROUND: Randomized trials demonstrate equivalent locoregional control with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) for T1-2 micrometastatic breast cancer, but include few mastectomy patients. Consensus is lacking on indications for post-mastectomy radiotherapy (PMRT) in this population. Herein, we evaluate locoregional recurrence (LRR) in an unselected, modern cohort of T1-2breast cancerpatients with micrometastases or isolated tumor cells (ITCs; N0i+/N1mi) having a mastectomy. METHODS: We identified patients with T1-2N0i+/N1mi breast cancer treated with mastectomy from January 2006 to December 2011. Recurrent, bilateral, and neoadjuvant cases were excluded. The primary outcome of interest was LRR. RESULTS: Overall, 352 patients [211 (60%) with ITCs and 141 (40%) with micrometastases] were identified. 162 (46%) patients had SLNB alone and one node was positive in 295 (84%) cases; 31 (9%) patients had PMRT and 95% had systemic therapy. At a median 6 years of follow-up, the overall crude LRR rate was 2.8% (n = 9), with no axillary recurrences, and the crude LRR rate was 3.9% among those who had SNB alone. Those with LRR had a median age of 55 years, median tumor size of 1.7 cm, and ductal histology; the majority were high-grade (89%) and estrogen receptor positive (78%), with one positive node (89%). There was no association between LRR and receipt of PMRT (p = 0.4), SLNB versus ALND (p = 0.2), or number of positive nodes (p = 0.7) using the log-rank test. CONCLUSIONS: LRR was infrequent among T1-2N0i+/N1mi patients treated with mastectomy without PMRT, with no axillary failures, suggesting that PMRT or nodal radiotherapy are not routinely indicated in this population.
Authors: G Cserni; D Gregori; F Merletti; A Sapino; M P Mano; A Ponti; S Sandrucci; B Baltás; G Bussolati Journal: Br J Surg Date: 2004-10 Impact factor: 6.939
Authors: A Wallgren; M Bonetti; R D Gelber; A Goldhirsch; M Castiglione-Gertsch; S B Holmberg; J Lindtner; B Thürlimann; M Fey; I D Werner; J F Forbes; K Price; A S Coates; J Collins Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert Journal: N Engl J Med Date: 2015-07-23 Impact factor: 91.245
Authors: Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi Journal: Lancet Oncol Date: 2013-03-11 Impact factor: 41.316
Authors: William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew Goetz; Lori J Goldstein; Clifford A Hudis; Steven J Isakoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena Moran; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2016-03 Impact factor: 11.908
Authors: Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen Journal: N Engl J Med Date: 2009-08-13 Impact factor: 91.245
Authors: Matthew S Katz; Linda McCall; Karla Ballman; Reshma Jagsi; Bruce G Haffty; Armando E Giuliano Journal: Breast Cancer Res Treat Date: 2020-02-10 Impact factor: 4.872
Authors: Eduardo Camargo Millen; Francisco Pimentel Cavalcante; Felipe Zerwes; Guilherme Novita; Alessandra Borba Anton de Souza; João Henrique Penna Reis; Helio Rubens de Oliveira Filho; Luciana Naíra de B L Limongi; Barbara Pace Silva de Assis Carvalho; Adriana Magalhães de Oliveira Freitas; Monica Travassos Jourdan; Vilmar Marques de Oliveira; Ruffo Freitas-Junior Journal: Ann Surg Oncol Date: 2021-09-27 Impact factor: 5.344
Authors: S Samiei; B N van Kaathoven; L Boersma; R W Y Granzier; S Siesling; S M E Engelen; L de Munck; S M J van Kuijk; R R J W van der Hulst; M B I Lobbes; M L Smidt; T J A van Nijnatten Journal: Ann Surg Oncol Date: 2019-07-29 Impact factor: 5.344
Authors: David Krug; René Baumann; Wilfried Budach; Marciana Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer Journal: Breast Care (Basel) Date: 2020-01-24 Impact factor: 2.860
Authors: Mausam Patel; Chenghui Li; Julia H Aronson; Cole M Howie; Sanjay Maraboyina; Arpan V Prabhu; Thomas Kim Journal: Breast Date: 2020-03-06 Impact factor: 4.380